title: Management of Multiple Myeloma with Second-Generation Antibody-Drug Conjugates.
abstract: The antibody-drug conjugate (ADC) is a combination of a cytotoxic agent and monoclonal antibodies (mAbs) through a stable specialized chemical linker. After ADC binds to the target antigen, the conjugate is internalized and toxin is released, leading to the death of a target cell. Lorvotuzumab mertansine, indatuximab ravtansine, and milatuzumab-doxorubicin are currently under clinical development for use in multiple myeloma (MM). Preliminary data from recent studies indicate that these agents induce responses in patients with relapsed and/or refractory MM and have an acceptable safety profile.
authors.affiliation: Department of Experimental Hematology, Medical University of Lodz, Lodz, Poland.
authors.forename: Pawel
authors.initials: P
authors.lastname: Robak
authors.affiliation: Department of Hematology, Medical University of Lodz, Ul. Ciolkowskiego 2, Lodz, Poland. robaktad@csk.umed.lodz.pl.
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018796:Immunoconjugates